At a glance
ClinicalIndex Comparison RecordN/ACompleted· 13,264 enrolled
Drug / intervention
Nintedanib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Characteristics of IPF Patients Initiating Nintedanib, Pirfenidone or no Antifibrotic Treatment in the US
In Brief
An observational study evaluating Nintedanib, Pirfenidone, and 1 other intervention for Idiopathic Pulmonary Fibrosis. Completed, enrolled 13,264 participants across 1 site.
Detailed Summary
To understand differences in characteristics of Idiopathic Pulmonary Fibrosis (IPF) patients who are prescribed nintedanib compared to those who are prescribed pirfenidone.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Fibrosis
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartFeb 2019
First PostedMay 2019
Primary CompletionMay 2019
TodayJul 2026
First PostedMay 21, 2019
Enrollment StartFeb 1, 2019
Primary CompletionMay 31, 2019
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 7.1 years ago
Interventions
Nintedanibdrug
Nintedanib initiators
Pirfenidonedrug
Pirfenidone initiators
Untreated Cohortother
Untreated